Abiopharma

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol EffluxMediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

Alto Neuroscience, Inc. - Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Incyte Appoints Bill Meury Chief Executive Officer;Hervé Hoppenot to Retire

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary